Cerenome vs RenovoRx
CNSY and RNXT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNSY and RNXT compare
RenovoRx is the larger company, worth 9.1 times as much as Cerenome ($55.1M against $6.1M).
RenovoRx keeps more of each dollar of sales as profit, with a net margin of −469% compared with −621% at Cerenome.
Cerenome scores higher on the StockData Score (8 against 6 for RenovoRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNSY | RNXT |
|---|---|---|
| Size and price | ||
| Market cap | $6.1M | $55.1M |
| Share price | $0.801 | $1.22 |
| Change, 1 year | −94.3% | 22.5% |
| Change, 5 years | −97.9% | −81.5% |
| Beta (5Y) | 0.55 | 1.32 |
| Employees | 28 | 17 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 19.8× |
| P/B | 1.1× (better) | 5.9× |
| FCF yield | −387% | −22.2% (better) |
| Fair value | $1.76 | $0.464 |
| Margin of safety | 54.6% (better) | −163% |
| Growth | ||
| Revenue growth (TTM) | −21.0% | – |
| Profitability | ||
| Gross margin | – | 84.0% |
| Operating margin | −628% | −489% (better) |
| Net margin | −621% | −469% (better) |
| FCF margin | −560% | −440% (better) |
| Return on equity | −614% | −150% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −1200.0× | – |
| Current ratio | 1.37 | 5.65 (better) |
| Altman Z-score | −58.28 | −0.01 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −18.2% |
| Shareholder yield | 0.00% (better) | −18.2% |
| Ownership | ||
| Held by institutions | 8.3% | 20.4% |
| Held by insiders | 4.2% | 6.0% |
| Insider net buying, 12 months | $0 | $66.9K (better) |
| Short interest, % of float | 11.6% | 2.4% |
Go deeper
- CNSY stock overview
- CNSY income statement
- CNSY valuation and score
- RNXT stock overview
- RNXT income statement
- RNXT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.